BioTransplant, Novartis Pharma AG deal

The companies will develop BTRN's ImmunoCognance mixed bone marrow chimerism technology, which creates immune tolerance to xenotransplantation.

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE